Results 151 to 160 of about 492,557 (263)
Dietary glutamine (Gln) supplementation increased the ATP levels and promoted cell proliferation in the rumen epithelium of feed‐restricted yaks. Besides, Gln inhibited ROS accumulation and reduced oxidative damage and apoptosis in the rumen epithelium of feed‐restricted yaks.
Ziqi Yue +10 more
wiley +1 more source
Mutant <i>HVEM</i> in lymphoma disrupts BTLA and CD160 regulation of anti-tumor signaling. [PDF]
Lin WW +8 more
europepmc +1 more source
Modulation of Animal Gut Health by Milk Oligosaccharide
This review summarizes the composition and structural characteristics of MOs across different mammalian species, and elucidates their roles and mechanisms in maintaining intestinal homeostasis by regulating gut microbiome and enhancing intestinal chemical, physical and immune barriers.
Ningtao Chen +7 more
wiley +1 more source
Correction to 'Advanced Lymphoblastic Lymphoma, NOS in Leukaemic Phase Presenting With Sudden and Fatal CNS Haemorrhage'. [PDF]
europepmc +1 more source
Dural Follicular Non-Hodgkin Lymphoma Mimicking a Chronic Subdural Hematoma: A Case Report and Literature Review. [PDF]
Arellanes-Chavez CA, Ramos Mertinez E.
europepmc +1 more source
Clock Genes Regulate Ca2+ Signaling and Mitochondrial Bioenergetics to Inhibit Sjögren Disease
Objective Although Ca2+ signaling and metabolism have been identified as key determinants for the development of Sjögren disease (SjD), the intricate connection between them and salivary gland physiology remains poorly understood. Methods Fluorescence‐based Ca2+ imaging, RNA sequencing, and mitochondrial activity were used to investigate the effects of
Viktor R. Drel +12 more
wiley +1 more source
Thymidine kinase 1 activity in serum and body cavity fluids of horses with lymphoma. [PDF]
Drozdzewska K +4 more
europepmc +1 more source
[Malignant lymphoma (Hodgkin lymphoma and non-Hodgkin lymphoma)].
openaire +2 more sources
Objective To characterize the clinical, immunologic, and proteomic changes associated with CD19 chimeric antigen receptor T cell therapy in patients with progressive systemic sclerosis (SSc). Methods Patients with progressive SSc received CD19 chimeric antigen receptor (CAR)‐T cell therapy and were observed longitudinally for safety, clinical efficacy,
Chenhan Jia +16 more
wiley +1 more source

